middle.news

Why Is Acrux Selling US Rights to Its Prilocaine/Lidocaine Cream Now?

9:35am on Friday 12th of December, 2025 AEDT Healthcare
Read Story

Why Is Acrux Selling US Rights to Its Prilocaine/Lidocaine Cream Now?

9:35am on Friday 12th of December, 2025 AEDT
Key Points
  • Divestment of US rights for Prilocaine/Lidocaine cream
  • Sale price of US$550,000 to be received in December 2025
  • Product no longer materially contributes to Acrux’s portfolio
  • Proceeds earmarked for Hormone Replacement Therapy (HRT) development
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Acrux (ASX:ACR)
OPEN ARTICLE